


UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
 United States Patent and Trademark Office  
 Address: COMMISSIONER FOR PATENTS  
 P.O. Box 1450  
 Alexandria, Virginia 22313-1450  
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/706,542	11/12/2003 FEB 2004	Linda S. Powers	13368.0001 (DIV. II)

K. S. Cornaby  
 Suite 1500  
 170 South Main Street  
 Salt Lake City, UT 84101-1644



CONFIRMATION NO. 6889

## FORMALITIES LETTER



\*OC000000011961660\*

Date Mailed: 02/25/2004

# NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:


- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

Replies should be mailed to: Mail Stop Missing Parts  
 Commissioner for Patents  
 P.O. Box 1450

Alexandria VA 22313-1450

---

*A copy of this notice MUST be returned with the reply.*

  
Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

LINDA S. POWERS; WALTHER R. ELLIS, JR.;  
CHRISTOPHER R. LLOYD

SER. NO.:

10/706,542

FILED:

11/12/03

FOR:

TAXONOMIC IDENTIFICATION OF PATHOGENIC  
MICROORGANISMS AND THEIR PROTEINS

RESPONSE

April 20, 2004

Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In reply to the Office Confirmation No. 6889 Formalities Letter dated February 25, 2004,  
- Notice to Comply With Requirements for Patent Applications Containing Nucleotide Sequence  
and/or Amino Acid Sequence Disclosures -, as requested, Applicants are transmitting the  
following:

1. An initial computer readable form copy of the "Sequence Listing";
2. A compact disc copy of the "Sequence Listing";
3. The following statement attesting to the content: The content of the sequence  
listing information recorded in computer readable form is identical to the written  
sequence listing and includes no new matter; and

4. A copy of the Notice to Comply With Requirements for Patent Applications  
Containing Nucleotide Sequences.

Applicants request that an Amendment be made directing that the "Sequence Listing" be entered into the specification.

Respectfully submitted,



---

K. S. Cornaby  
Jones Waldo Holbrook & McDonough PC  
Attorneys for Applicants  
170 South Main Street, Suite 1500  
Salt Lake City, UT 84101  
(801) 521-3200  
ksc@joneswaldo.com

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service Express Mail EV 333426267 US in an envelope addressed to Mail Stop Missing Parts, Commissioner for Patents, Alexandria, VA 22313-1450 on the 20<sup>th</sup> day of April, 2004.

  
Roberta M. Kelly